Danne T, Edelman S, Frias JP, Ampudia-Blasco FJ, et al. Efficacy and safety of adding sotagliflozin, a dual SGLT1 and SGLT2 inhibitor, to optimized insulin therapy in adults with type 1 diabetes and baseline BMI >/=27 kg/m(2). Diabetes Obes Metab 2020 Dec 2. doi: 10.1111/dom.14271.
PMID: 33289297